Prognostic impact of tissue factor pathway on long-term ischemic events of ST-elevated myocardial infarction treated with a primary percutaneous coronary intervention

Sambola, Antonia; Blanco, Bruno García del; Francisco, Jaume; Figueras, Jaume; Martí, Gerard; Roca, Ivo; Otaegui, Imanol; Garcı́a-Dorado, David

doi:10.1016/j.ijcard.2013.03.188

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, we now demonstrate that plasma TF activity in post-AMI patients follows a similar V-shaped temporal pattern over 6-month follow-up. Similar dynamic change of plasma TF activity in post-AMI patients was also observed by Sambola et al (22). These findings suggest that the sampling time point could significantly confound TF levels.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Plasma tissue factor coagulation activity in post-acute myocardial infarction patients

et al. 2022

View full text Add to dashboard Cite

IntroductionCoagulation is involved in fibroproliferative responses following acute myocardial infarction (AMI). Left ventricular (LV) remodeling following AMI is closely associated with progression to heart failure. This study aims to assess the association between plasma tissue factor activity and LV remodeling in post-AMI patients.MethodsWe studied 228 patients with AMI and 57 healthy subjects. Patients with AMI were categorized into two age- and sex-matched groups: patients with adverse LV remodeling or reverse LV remodeling, defined by an increase or decrease, respectively, in LV end systolic volume by ≥15% over 6 months. TF activity was measured in plasma collected at baseline (within 72 hours of revascularization), 1 month and 6 months post-AMI. Multiple level longitudinal data analysis with structural equation (ML-SEM) model was used to assess the impact of various clinical variables on TF activity in post-AMI.ResultsPlasma TF activity in post-AMI patients at baseline (29.05 ± 10.75 pM) was similar to that in healthy subjects but fell at 1 month (21.78 ± 8.23, p<0.001) with partial recovery by 6 months (25.84 ± 8.80, p<0.001) after AMI. Plasma TF activity at 6 month post-AMI was better restored in patients with reverse LV remodeling than those with adverse LV remodeling (27.35 ± 7.14 vs 24.34 ± 9.99; p=0.009) independent of gender, age and relevant cardiovascular risk factors.ConclusionsPlasma TF activity decreased after AMI but was better restored at 6 months in patients with reverse LV remodeling. The clinical significance of changes in post-AMI plasma TF activity needs further investigation.

show abstract

Section: Discussionsupporting

confidence: 87%

“…TF has been associated with AMI occurrence and post-AMI adverse events including mortality (18)(19)(20)(21)(22)(23). Although the involvement of TF in AMI and post-AMI LV remodeling was reported in preclinical animal models (9,27), the contribution of TF in post-AMI LV remodeling in human patients remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Plasma tissue factor coagulation activity in post-acute myocardial infarction patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Tissue factor activity (TFa), tissue factor pathway inhibitor (TFPI), and thrombin-activatable fibrinolysis inhibitor (TAFI) were quantified using commercially available chromogenic kits, (Gentaur, Paris, France, and Hyphen BioMed, Neuville-sur-Oise, France, respectively). Internal validation of the measures has been published previously (10)(11)(12). Plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) Ag were determined by ELISA (Menarini Biopool, Malmö, Sweden).…”

Section: Laboratory Studiesmentioning

confidence: 99%

Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy

Sambola¹,

Blanco²,

Ruiz‐Meana³

et al. 2016

Thromb Haemost

Self Cite

View full text Add to dashboard Cite

Therapeutic fibrinolysis is ineffective in 40 % of ST-segment elevation acute myocardial infarction (STEMI) patients, but understanding of the mechanisms is incomplete. It was our aim to compare the composition of coronary thrombus in lysis-resistant STEMI patients with that of lysis-sensitive patients. Intracoronary thrombi (n=64) were obtained by aspiration in consecutive STEMI patients. Of them, 20 had received fibrinolysis and underwent rescue percutaneous coronary intervention (r-PCI, lysis-resistant patients) and 44 underwent primary PCI (p-PCI). Lysis-sensitivity was determined in vitro by clot permeability measurements and turbidimetric lysis in plasma of 44 patients undergoing p-PCI and 20 healthy donors. Clot-lysis sensitivity was defined as a clot-lysis time not greater than 1 SD over the mean of healthy donors. Coronary thrombus composition in 20 lysis-resistant and in 20 lysis-sensitive patients was analysed by immunofluorescence with confocal microscopy. Plasma biomarkers (P-selectin, VWF, PAI-1, t-PA, D-dimer, TF pathway markers, plasmin and CD34+) were measured simultaneously on peripheral blood. Lysis-resistant clots had higher levels of fibrin (p=0.02), P-selectin (p=0.03) and VWF (p=0.01) than lysis-sensitive clots. Among thrombi obtained ≤ 6 hours after onset of symptoms, those from lysis-resistant patients showed a higher content in fibrin than those from p-PCI patients (p=0.01). Plasma PAI-1 (p=0.02) and D-dimer levels were significantly higher (p=0.003) in lysis-resistant patients, whereas plasmin levels were lower (p=0.03). Multivariate analysis showed the content of fibrin and VWF within thrombus as predictors of thrombolysis resistance. In conclusion, coronary thrombi in STEMI patients resistant to fibrinolysis are characterised by higher fibrin, P-selectin and VWF content than lysis-sensitive thrombi.

show abstract

Tissue factor pathway inhibitor is an early biomarker of myocardial injury in patients with ST-segment elevation acute myocardial infarction

Sambola

Francisco

Blanco

et al. 2014

International Journal of Cardiology

View full text Add to dashboard Cite

Prognostic impact of tissue factor pathway on long-term ischemic events of ST-elevated myocardial infarction treated with a primary percutaneous coronary intervention

Cited by 5 publications

References 9 publications

Plasma tissue factor coagulation activity in post-acute myocardial infarction patients

Plasma tissue factor coagulation activity in post-acute myocardial infarction patients

Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy

Tissue factor pathway inhibitor is an early biomarker of myocardial injury in patients with ST-segment elevation acute myocardial infarction

Contact Info

Product

Resources

About